Lotus Pharmaceutical has announced a share buyback program, demonstrating confidence in its strong fundamentals and long-term growth potential. The company plans to repurchase up to 4 million shares on the open market between April 11 and June 9, with a buyback price range of NT$180 to NT$245 per share, representing approximately 1.51% of its total outstanding shares.

Dr. Petar Vazharov, CEO of Lotus Pharmaceutical, stated that the current share price does not fully reflect the company's true value, which includes its solid operational foundation and promising product pipeline. He emphasized that Lotus has a comprehensive strategy to address future risks. The buyback initiative not only serves as a way to reward shareholders but also helps manage the costs associated with future employee equity incentive plans.

The company noted that with a robust financial structure and strong cash flow, it is well-positioned to carry out the buyback while continuing to invest in key areas for long-term development. With innovation at its core, Lotus will keep expanding its product portfolio and accelerating market growth across the Asia-Pacific region.

On the R&D front, Lotus is establishing a new research center in Genome Valley, Hyderabad, India, focusing on the early development of high-value products to enhance competitiveness. The company’s recent strategic acquisitions in Southeast Asia have delivered outstanding results, with revenue in Thailand and Vietnam increasing by 500% and 800% year-on-year, respectively. Lotus will continue to actively explore further M&A opportunities to strengthen its leadership position in the Asia-Pacific market.

Resource: 美時宣布實施庫藏股計畫 買回最多400萬股 每股價格180~245元